Automated radiosynthesis of Ga for large-scale routine production using Zn pressed target.

Appl Radiat Isot

Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 12e Avenue Nord, Sherbrooke, QC, J1H 5N4, Canada; Sherbrooke Molecular Imaging Center (CIMS) of the CRCHUS, 3001, 12e Avenue Nord, Sherbrooke, QC, J1H 5N4, Canada. Electronic address:

Published: February 2020

Gallium-68 (Ga) has attracted increasing interest in recent years due to the expanding clinical applications of Ga-based radiopharmaceuticals (Rahbar et al., 2017). Ga is mainly produced via Ge/Ga generators that are limited in yield by the Ge activity (typically up to 1.85 GBq at calibration time). With the increased-demand of Ga in nuclear medicine for positron emission tomography (PET) imaging, there is a need for more efficient and robust production methods to obtain larger amounts of [Ga]GaCl with high radionuclidic and radiochemical purity and apparent molar activity (AMA) for facilitating the distribution of Ga-based radiopharmaceuticals. The objectives of this study were to develop a fast and efficient process for the preparation of Zn-based solid targets and to optimize the critical parameters for the automated radiosynthesis of [Ga]GaCl for large-scale routine production.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apradiso.2019.109014DOI Listing

Publication Analysis

Top Keywords

automated radiosynthesis
8
large-scale routine
8
routine production
8
ga-based radiopharmaceuticals
8
radiosynthesis large-scale
4
production pressed
4
pressed target
4
target gallium-68
4
gallium-68 attracted
4
attracted increasing
4

Similar Publications

Lead-it-EAZY! GMP-compliant production of [Pb]Pb-PSC-PEG-TOC.

EJNMMI Radiopharm Chem

November 2024

Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstr. 74, 01307, Dresden, Germany.

Background: Recently, radiotheranostics comprising the true matched radionuclide pair Pb could serve as real dosimetric planning utility using Pb-radiolabelled pharmaceuticals before therapy with Pb-radiolabelled counterparts. Pb might act as the missing radionuclide therapy between standard β therapies (e.g.

View Article and Find Full Text PDF

Improved Automated Radiosynthesis of [F]Dolutegravir: Toward Clinical Applications.

ACS Omega

October 2024

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay (BioMaps), Orsay 91401, France.

Positron emission tomography imaging using radiolabeled dolutegravir (DTG) is an interesting approach to understand the biodistribution of this antiretroviral drug at HIV-1 sanctuary sites. In the course of clinical translation, we depict herein an improved and pharmaceutically compliant radiosynthesis of [F]DTG from an original tin precursor. The radiosynthesis was achieved in two steps by copper-mediated radiofluorination, followed by enol ether deprotection using a kit-based AllInOne module.

View Article and Find Full Text PDF

Cerebral blood flow and blood-brain barrier permeability assessment are crucial hemodynamic parameters to measure under neurological conditions. In conjunction with positron emission tomography (PET), oxygen-15-labeled water has emerged as a gold standard for measuring cerebral perfusion; however, at higher flow rates, [O]water extraction becomes nonlinear. In such a scenario, freely diffusible [C]butanol can provide a truer estimate.

View Article and Find Full Text PDF

Background: A novel positron emission tomography (PET) imaging tracer, [F] SynVesT-1, targeting synaptic vesicle glycoprotein 2 (SV2A), has been developed to meet clinical demand. Utilizing the Trasis AllinOne-36 (AIO) module, we've automated synthesis to Good Manufacturing Practice (GMP) standards, ensuring sterile, pyrogen-free production. The fully GMP-compliant robust synthesis of [F] SynVesT-1 boosting reliability and introducing a significant degree of simplicity and its comprehensive validation for routine human use.

View Article and Find Full Text PDF

The most prominent myocardial voltage-gated sodium channel, Na1.5, is a major drug target for treating cardiovascular disease. However, treatment determination and therapeutic development are complicated partly by an inadequate understanding of how the density of SCN5A, the gene that encodes Na1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!